Loading news...
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.02, indicating a +2.24% shift from the previous trading day.
- Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively – - Humacyte's Symvess® has consistently demonstrated low rates of infection and high rates of limb salvage – DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the results of a five-year retrospective analysis of hospital charges, payer costs, and healthcare resource utilization in patients with extremity arterial injury.
Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of the acellular tissue engineered vessel (ATEV™ or Symvess) for arterial trauma repair during the first quarter of 2026.
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma patients in the Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT).
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes for dialysis patients suffering from Steal syndrome who were treated with the ATEV – – Additional presentations report durable two-year outcomes for patients treated in Ukraine conflict, superior two-year outcomes for female dialysis patients, and results for patients treated with torso arterial trauma – DURHAM, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced highlights of five podium presentations on the Company's acellular tissue engineered vessel (ATEV™) made yesterday at the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizons (VEITHsymposium), in New York, NY.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six presentations on the Company's acellular tissue engineered vessel (ATEV™) that are scheduled for the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizons (VEITHsymposium), to be held November 18-22, 2025 in New York, NY.
Humacyte, Inc. ( HUMA ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Laura Niklason - Founder, President, CEO & Director Dale Sander - CFO, Chief Corporate Development Officer & Treasurer Conference Call Participants Thomas Johnson - Lifesci Advisors, LLC Sneha Muthe - Barclays Bank PLC, Research Division Iseult McMahon - BTIG, LLC, Research Division Joshua Jennings - TD Cowen, Research Division Jason Kolbert - D. Boral Capital LLC, Research Division Bruce Jackson - The Benchmark Company, LLC, Research Division Swayampakula Ramakanth - H.C.
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.33 per share a year ago.
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-need patients could greatly reduce reliance on catheters for dialysis access, a major cause of complications, morbidity and cost in dialysis patients – DURHAM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of positive two-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous (AV) access for hemodialysis patients at the American Society of Nephrology's (ASN) Kidney Week 2025, the premier nephrology meeting, in Houston.
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.31, representing a -10% change from its previous close.
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.62, indicating a -4.14% shift from the previous trading day.
- Results published in AAST's Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT registry, outcomes for Symvess and autologous vein were similar for treatment of vascular trauma - DURHAM, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of a new study comparing clinical outcomes of Symvess to autologous vein in the treatment of extremity arterial trauma.
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.71, representing a +1.18% change from its previous close.
Humacyte, Inc. (HUMA) closed at $1.72 in the latest trading session, marking a +1.18% move from the prior day.